The HRAS Knockout SK-HEP-1 Polyclonal Cells product offers researchers a heterogeneous pool of CRISPR/Cas9-edited SK-HEP-1 cells, in which the HRAS gene has been disrupted to establish a polyclonal loss-of-function model. Derived from a human liver adenocarcinoma patient, SK-HEP-1 cells display an endothelial-like hepatocellular carcinoma phenotype, closely mimicking liver sinusoidal endothelial cells. The polyclonal nature of this knockout population reflects the inherent variability of CRISPR/Cas9-mediated gene editing across individual cells, enabling studies that do not rely on single-cell clonal expansion. This product is designed for investigators requiring a biologically relevant tool to interrogate HRAS function in a liver cancer context without the bias of clonal selection.
SK-HEP-1 cells were originally isolated from the ascites of a patient with liver adenocarcinoma and are characterized by a unique endothelial-like phenotype. They express markers typical of both hepatocytes and endothelial cells, making them a valuable model for studying liver sinusoidal endothelial cell biology, hepatocellular carcinoma progression, and tumor angiogenesis. The cell line has been extensively used to investigate mechanisms of cancer cell migration, invasion, and drug resistance. Combining this platform with CRISPR/Cas9-mediated disruption of HRAS provides a powerful system to dissect the contributions of the HRAS protein within the complex tumor microenvironment.
HRAS is a prototypic member of the Ras superfamily of small GTPases, functioning as a binary molecular switch that cycles between an inactive GDP-bound state and an active GTP-bound conformation. Activation occurs in response to diverse growth factors??including those acting through EGFR, FGFR, PDGFR, and GPCRs??via the adaptor protein GRB2 and the guanine nucleotide exchange factor SOS1. Upon activation, HRAS engages multiple downstream effector cascades. It directly interacts with and activates RAF1 (and BRAF) to initiate the MEK1/2?CERK1/2 mitogen-activated protein kinase module, promoting cell proliferation and differentiation. Additionally, HRAS recruits and activates PI3K to stimulate AKT?CmTOR signaling, a central pathway controlling cell survival, growth, and metabolism. HRAS also signals through RALGDS to activate RalA and RalB GTPases, which regulate vesicle trafficking and cytoskeletal dynamics, and through PLC??, which generates second messengers DAG and IP3 to mobilize calcium and activate protein kinase C. Other interacting factors, such as TIAM1, further modulate Rac signaling and cell motility. Thus, HRAS coordinates a broad network of downstream effectors that integrate proliferation, survival, and cytoskeletal rearrangements.
Loss of HRAS function in SK-HEP-1 cells is particularly informative because this cell line retains an endothelial-like character and is frequently used to model liver cancer and angiogenesis. Disruption of HRAS expression in this background allows researchers to selectively determine the contribution of HRAS-mediated signaling to endothelial-like behaviors, including tube formation, migration, and barrier function, as well as hepatocellular carcinoma cell growth and survival. Given that HRAS mutations are implicated in several human cancers??such as bladder cancer, thyroid carcinoma, and squamous cell carcinoma??this model may also provide insight into mutant HRAS-driven oncogenesis. Moreover, the SK-HEP-1 line??s origin from a metastatic effusion endows it with properties relevant for studying metastatic dissemination. The combined knockout and cell model thus enables rigorous dissection of HRAS-dependent pathways in a context that bridges hepatocellular carcinoma and angiogenic processes.
Typical experimental applications of these polyclonal knockout cells include the analysis of HRAS-dependent signal transduction by monitoring phosphorylation levels of ERK1/2 and AKT via western blotting, as well as evaluating changes in HRAS mRNA expression through RT-qPCR. The cells are well suited for functional assays such as MTT-based proliferation measurements, anchorage-independent growth in soft agar, and migration/invasion assays using Boyden chambers, thereby allowing assessment of HRAS??s role in transformation and metastatic potential. Because HRAS is a validated therapeutic target, this model is also valuable for drug sensitivity profiling and screening assays aimed at Ras pathway inhibitors. Researchers can use the polyclonal knockout population to study resistance mechanisms that may emerge under therapeutic pressure. For further technical details or assistance with experimental design, please contact Ascent Research.
